Form 4: Director Leslie J. Williams Receives Equity Grant

Ocular Therapeutix director Leslie J. Williams was granted 14,000 restricted stock units and 44,000 stock options.

Summary

• Director Leslie J. Williams received a grant of 14,000 restricted stock units (RSUs) on June 10, 2026.
• The director also received a grant of 44,000 stock options with an exercise price of $8.74 per share.
• Both the RSUs and the stock options are scheduled to vest 100% on the first anniversary of the grant date or immediately prior to the next annual meeting of stockholders, whichever is earlier.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation that carries no significant change in company strategy or financial outlook.

Positives

• Equity-based compensation aligns the interests of the director with those of the shareholders.
• The grants are subject to continued service on the board of directors, incentivizing long-term retention.

Negatives

• The issuance of new equity grants results in potential future dilution for existing shareholders.

Risks

• The value of the granted equity is subject to market volatility and the future performance of the company's common stock.

Future Outlook

The equity grants are subject to vesting conditions based on continued service on the board of directors through the first anniversary of the grant or the next annual meeting.

Industry Context

StockSavvy.ai notes that equity grants to board members are standard corporate governance practice in the biotechnology sector to ensure alignment between leadership and shareholder interests.

Comparison to Industry Standards

• The use of 1-year cliff vesting for director equity is consistent with standard practices for small-to-mid-cap biotechnology companies.

Stakeholder Impact

• Shareholders may experience minor dilution upon the eventual exercise or vesting of these equity instruments.

Next Steps

• Vesting of RSUs and options on the first anniversary of the grant or the next annual meeting of stockholders.

Key Dates

Keywords

Ocular Therapeutix, OCUL, Form 4, Insider Trading, Equity Compensation, Director Compensation